Mahmoudreza Moein

Dr. Mahmoudreza Moein

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Surgery in Practice and Science
Verified
Journal Article
Open access
MMMahmoudreza Moein
Mahmoudreza Moein
JCJonathan Capelin
Jonathan Capelin
JTJoseph F. Toth
Joseph F. Toth
DTDylan Tylor
Dylan Tylor
ZWZoe M. Weiss
Zoe M. Weiss
RSReza F. Saidi
Reza F. Saidi

20 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
AGAlexandra Goodman
Alexandra Goodman
DDDevashish Desai
Devashish Desai
DPDean Pavlick
Dean Pavlick
KGKrishna Bilas Ghimire
Krishna Bilas Ghimire
Background/Objectives: This study investigates genomic alterations (GA) between NPM1-mutated (NPM1mut) and wild-type (NPM1wt) acute myeloid leukemia (AML), aiming to better understand the AML genomic profile. NPM1mut AML represents a distinct clinical AML subtype with high relapse rates despite initial responsiveness to chemotherapy. Methods: A total of 4206 AML cases from 2019 to 2024 were analyzed using the FoundationOne Heme assay, incorporating comprehensive DNA and RNA sequencing. Patients were stratified into NPM1mut and NPM1wt cohorts, and genomic differences were systematically compared between the two groups. Results: Among 4206 cases, 633 (15.1%) featured NPM1 GA, with over 99% exhibiting short variant mutations. NPM1mut AML was more common in females (53.4% vs. 41.5%) and associated with a slightly higher median age (62 vs. 60 years). GA was more frequent in NPM1mut AML compared to the NPM1wt and included DNMT3A (39.2% vs. 12.6%; p < 0.0001), PTPN11 (18.3% vs. 7.5%; p < 0.0001), FLT3 (54.5% vs. 14.7%; p < 0.0001), IDH1 (16.1% vs. 5.6%; p < 0.0001), IDH2 (19.0% vs. 9.0%; p < 0.0001), TET2 (23.4% vs. 13.5%; p < 0.0001), and WT1 (12.5% vs. 9.4%; p = 0.02). GA was more frequent in NPM1wt AML and included ASXL1 (17.1% vs. 3.6%; p 0.0001), BCOR (7.5% vs. 1.6%; p < 0.0001), KMT2A (14.7% vs. 0.2%; p < 0.0001), RUNX1 (22.5% vs. 1.9%; p 0.0001), STAG2 (6.9% vs. 1.6%; p < 0.0001) and TP53 (19.1% vs. 4.1%; p < 0.0001). Conclusions: Mutations linked to therapy targets in AML, such as (FLT3 and IDH1/2), PTPN11, and DNMT3A (both associated with inferior outcomes), are more commonly observed in NPM1mut AML, whereas KMT2A, TP53, and myelodysplastic-related mutations are more commonly observed in NPM1wt AML.

2 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
NNNour Sabiha Naji
Nour Sabiha Naji
APAnsy Patel
Ansy Patel
AMAnupa R. Mandava
Anupa R. Mandava
KGKrishna B. Ghimire
Krishna B. Ghimire
Background: The KMT2A (MLL1) gene is altered in a variety of hematological malignancies and solid tumors. KMT2A-rearranged (KMT2Ar) AML represents a distinct subtype associated with poor outcomes and high relapse rate despite initial responsiveness to chemotherapy. Methods: A total of 3863 cases of AML peripheral blood samples were analyzed using the FoundationOne Heme combined comprehensive hybrid capture-based DNA and RNA sequencing assay. Results: Of the 3863 AML cases, 521 (13.4%) featured genomic alterations (GAs) in the KMT2A gene, 99.1% of which were large rearrangements (KMT2Ar). A total of 56.9% were males with a median age of 62 years. Of the KMT2Ar cases, there were 43.1% KMT2A duplications, 52.7% fusions, and 4.2% not otherwise specified rearrangements. A total of 0.9% of the KMT2A-altered AML cases were short variant mutations. There were no KMT2A (0%) amplifications or deletions. KMT2Ar cases were associated with increased GA frequencies in FLT3 (27.3% vs. 19.8%; p = 0.0002), KRAS (17.2% vs. 7.8%; p < 0.0001) (overall; 1.1% KRAS G12C), and IDH2 (16.0% vs. 10.4%; p < 0.0001), while KMT2A wild-type AML (KMT2Awt) had significantly increased GA frequencies in RUNX1 (20.7% vs. 15.8%; p = 0.0081), ASXL1 (16.6% vs. 10.5%; p = 0.0003), and TET2 (16.4% vs. 10.1%; p = 0.0002), NPM1 (17.5% vs. 0.2%; p < 0.0001), and TP53 (17.8% vs. 7.9%; p < 0.0001). Conclusions: KMT2A rearrangements are common in AML (13.4% of cases featured KMT2Ar). A total of 99.1% of alterations in KMT2A are large rearrangements, with fusions being the most commonly observed alteration (52.7% of total rearrangements). No amplifications or deletions were seen. This genomic landscape study highlights significant genomic differences between KMT2Ar and KMT2Awt AML patients, which may enrich our understanding of the molecular profile and clusters of mutations in AML.

13 September 2022 in Transplantation
Verified
Journal Article
Open access
MMMahmoudreza Moein
Mahmoudreza Moein
SISamir Iskhagi
Samir Iskhagi
RSRauf Shahbazov
Rauf Shahbazov
ABAngela Ball
Angela Ball
SLSharon Loerzel
Sharon Loerzel
RSReza Saidi
Reza Saidi

28 April 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
BBBehrouz Broumand
Behrouz Broumand
MMMahmoudreza Moein
Mahmoudreza Moein
RSReza F. Saidi
Reza F. Saidi

13 September 2022 in Transplantation
Verified
Journal Article
Open access
RDReut Hod Dvorai
Reut Hod Dvorai
MMMahmoudreza Moein
Mahmoudreza Moein
RTReeba Thankachan
Reeba Thankachan
JLJohn Leggat
John Leggat
ESEman Shaban
Eman Shaban
RSReza Saidi
Reza Saidi